A Phase 3 interventional study of Tranexamic Acid and Placebos in Fibroid Uterus, Abnormal Uterine Bleeding and Myoma;Uterus, sponsored by Eastern Virginia Medical School. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.
Sponsored by Eastern Virginia Medical School · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies in Leiomyoma with a site in United States — 19 open to participants now, 29 under way, 3 of them phase 3. Leiomyoma · United States.
Among the 156 studies in Leiomyoma with a site in United States, this one is the 66th largest by planned enrollment of the 121 interventional ones that give a count, is one of 8 that started in 2020, is one of 31 in phase 3, reaches primary completion later than 0 of the 27 other live ones, and was the 111th registered.
439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →19 of the 156 studies in Leiomyoma with a site in United States are open now. Recruiting first, the newest first:
Christiana Care Health Services · Sites in United States
Ages 18+ · Women only
Northwestern University · Sites in United States
Ages 18–50 · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
Johns Hopkins University · Sites in United States
Ages 18+ · Women only
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 21 · Phase 3 32 · Phase 4 17
First in 1995; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 66 across 307 interventional studies indexed under Leiomyoma.
Median enrollment 57 across the 121 interventional studies, 187 across the 34 observational. Of the 113 that completed or were terminated, 59 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 156 have an industry lead sponsor. The 10 most frequent:
Eastern Virginia Medical School is the lead sponsor of 56 studies on the registry; 7 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Eastern Virginia Medical School has 1 study filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
10 of the studies in Leiomyoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07078682Zenchi, Inc.An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms | 2026-11 |
| NCT07286188Northwestern UniversityEffect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy | 2026-12 |
| NCT06536517Johns Hopkins UniversityThe Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | 2026-12 |
| NCT04126824University of California, Los AngelesEffect of Addition of Steroids on Duration of Analgesia | 2026-12-30 |
| NCT05386615InSightecPost-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 156 studies in Leiomyoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Double-blinded randomized placebo-controlled trial based at Eastern Virginia Medical School. Subjects who are identified in clinic having menorrhagia or abnormal Uterine bleeding (AUB) due to uterine fibroids and meet inclusion criteria based on the ultrasound (US) or Magnetic Resonance Imaging (MRI), aged 18-45 undergoing laparoscopic or Robotic assisted myomectomies. A total of 50 women in each arm of the study with symptomatic fibroids. Patients will be randomized to receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline (intervention group) versus an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision.
This is a Double-blinded randomized placebo-controlled trial based at Eastern Virginia Medical School. Subjects who are identified in clinic having menorrhagia or abnormal Uterine bleeding (AUB) due to uterine fibroids and meet inclusion criteria based on the ultrasound (US) or Magnetic Resonance Imaging (MRI), aged 18-45 undergoing laparoscopic or Robotic assisted myomectomies. These subjects will be then approached for consent during their pre-op visit 1-2 weeks prior to their surgery. The setting for consent will be in a patient consultation room. A total of 50 women in each arm of the study with symptomatic fibroids meeting any of the following criteria will be included in the study:
Both surgeon and patient will be blinded to the treatment arm. This dosage has been used previously in both obstetric and gynecological procedures and is the same dose recommended by the WHO for preventing post-partum hemorrhage The surgery itself will be scheduled at either Sentara Norfolk General, Sentara Leigh hospital, and Sentara Princess Anne hospital. These are the three sites that the investigators already perform Minimally invasive myomectomies.
An envelope will be given to the anesthesiologist prior to the procedure informing whether they are to receives TXA or the placebo. Blood loss will be estimated by the surgeon performing the procedure. Hemoglobin and hematocrit will be obtained 24 hours post procedure. The patient will be assessed for reported side effects from the medication given will be assessed by a questionnaire that will be given at their post-op appointment at the 2 week and 6-week mark. During these two visits a physical exam is performed, checking incision sites, and patient symptoms, all of which are standard of care for any minimally invasive procedure. The patients will be seen at the EVMS outpatient clinic for Gynecology, or depending with the physician who performed the surgery. Data will be collected from both Allscripts and EPIC charts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a single IV bolus injection of TXA 30mg/kg in 50ml of normal saline 15 minutes prior to initial surgical incision time
Drug: Tranexamic Acid
Patients will receive an IV bolus injection of normal saline of equivalent volume (placebo group) 15 minutes prior to initial surgical incision
Drug: Placebos
IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
Estimated blood loss
Estimated blood loss at time of procedure completion; using volume of cannister and weight of lap sponges
Time frame: Duration of procedure up to 420 minutes
Calculated blood loss
Calculated Blood loss, using pre-operative hematocrit, postoperative hematocrit and estimated blood volume x Body Mass Index
Time frame: From post operative day 0 until postoperative day 1
Number of blood products received
Number of blood products received during admission that is directly due to blood loss at time of procedure
Time frame: Duration of hospital stay up to two days
Duration of surgery
Start time of procedure until end time of procedure
Time frame: Duration of surgery up to 420 minutes
Length of hospital stay
Recorded in days
Time frame: Duration of stay in hospital, up to two days
Number of fibroids removed
Total number of fibroids removed during procedure
Time frame: Duration of surgery, up to 420 minutes
Fibroid type
type of fibroid per FIGO classification
Time frame: through completion of study average 8 weeks
Weight of fibroids removed
total weight of fibroids removed
Time frame: duration of surgery up to 420 minutes
Pain index
Pain index score on postoperative day 1 and 14 Score of 0-10 0 = no pain, 10 = significant amount of pain
Time frame: duration of hospital stay, up to two days
Incidence of postoperative complication
Immediate postoperative complication: Hemorrhage Infection Fever Deep vein thrombosis Hysterectomy Re-exploration Hospital readmission
Time frame: Duration of hospital stay , up to two days
Questionnaire for incidence of mild side effect of medication
Reported mild effective of medication of post operative day 1
Time frame: only on postoperative day 1 , one day
Questionnaire for incidence of serious side effect of medication
Reported serious side effect of medication on post operative day 1
Time frame: Only on postoperative day 1, one day
tPA receptor
Percentage of tPA receptor located in fibroid and myometrium
Time frame: From time of randomization until postoperative visit, four weeks
PAI-1 receptor
Percentage of PAI-1receptor located in fibroid and myometrium
Time frame: From time of randomization until postoeprative visit, four weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jun 2020 (actual). Primary completion is estimated for Jul 2024, 49 months after the start.
Of 25 phase 3 interventional studies under Leiomyoma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 41. This study's planned 49 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Eastern Virginia Medical School